Annexon
ANNXAnnexon is a clinical-stage biopharmaceutical company developing a proprietary platform of targeted immunotherapies for complement-mediated neuroinflammatory diseases.
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Annexon is a clinical-stage biopharmaceutical company developing a proprietary platform of targeted immunotherapies for complement-mediated neuroinflammatory diseases. The company focuses on inhibiting C1q, the initiating molecule of the classical complement pathway, to protect the body, brain, and eye from aberrant immune activation. Their approach aims to halt disease progression in autoimmune, neurodegenerative, and ophthalmic conditions while preserving beneficial immune functions.
A leader in C1q-targeted inhibition with late-stage registrational programs in Guillain-Barré Syndrome and Geographic Atrophy.
Questions, answered.
- What is Annexon's market cap?
- Annexon (ANNX) has a market capitalization of $840.5M and trades on NASDAQ.
- Who are Annexon's competitors?
- Annexon's key competitors include Regeneron Pharmaceuticals, Dianthus Therapeutics, Inc. Common Stock, Nkarta, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Annexon partner with?
- Annexon's notable partners include Stanford University, The J. David Gladstone Institutes, University of California, and others.
- Where is Annexon headquartered?
- Annexon is headquartered in United States of America and employs approximately 70 people. It has been publicly traded since 2020.